Prophylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD mice

Prophylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD mice

Abstract Introduction Alzheimer's disease (AD) is the most common form of dementia. Beta‐secretase (BACE) inhibitors have been proposed as potential therapeutic interventions; however, initiating treatment once disease has significantly progressed has failed to effectively stop or treat disease...

Full description

Saved in:
Bibliographic Details
Main Authors: Adrian L. Oblak, Zackary A. Cope, Sara K. Quinney, Ravi S. Pandey, Carla Biesdorf, Andi R. Masters, Kristen D. Onos, Leslie Haynes, Kelly J. Keezer, Jill A. Meyer, Jonathan S. Peters, Scott A. Persohn, Amanda A. Bedwell, Kierra Eldridge, Rachael Speedy, Gabriela Little, Sean‐Paul Williams, Brenda Noarbe, Andre Obenaus, Michael Sasner, Gareth R. Howell, Gregory W. Carter, Harriet Williams, Bruce T. Lamb, Paul R. Territo, Stacey J. Sukoff Rizzo
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
amyloid
BACE inhibitor
MODEL‐AD
mouse model
preclinical testing
Online Access:https://doi.org/10.1002/trc2.12317
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/trc2.12317

Similar Items